Project Grant F30DA062497

Award Date 6/19/25
Completion Date Not listed
Dollars Obligated $43K
Federal Grant Program
93.279
Assistance Type
Project Grant
Place of Performance
Birmingham, AL 35294, USA
Similar Awards
This Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), is focused on investigating a specialized serotonergic-septohippocampal circuit that may influence the vulnerability for relapse in substance use disorders. The $254,250 award, spanning from July 2024 to June 2026, will support the delineation of the intrinsic properties and transmission interactions of a novel neuronal cell type (LSI-R2P) that is modulated...
This $751,043 federal Project Grant award from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) supports research investigating the cellular and molecular mechanisms underlying the complex co-occurrence of opioid use disorder (OUD), major depressive disorder (MDD), and HIV in the human brain. The award will fund a comprehensive study using advanced multi-omics approaches, including single-nucleus RNA sequencing and single-nucleus ATAC...
This $373,300 Project Grant award from the National Institute on Drug Abuse (NIDA), under the federal Drug Use and Addiction Research Programs (CFDA 93.279), will support research to investigate the role of the nucleus accumbens (NAc) in learning and responding to reward-predictive cues. The research aims to enhance understanding of the neural activity dynamics in NAc that contribute to selective conditioned responses to reward-paired cues versus neutral cues. Using an auditory Pavlovian...
This Project Grant award from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) provides $149,284 to the University of Washington to investigate the role of prefrontal cortex pyramidal neuron subpopulations in regulating drug-seeking behavior. The research will use fiber photometry and chemogenetic techniques to characterize alterations to intratelencephalic (IT) and pyramidal tract (PT) neuron activity in the prelimbic region of the...
This Project Grant award from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) provides $629,844 to Duke University to elucidate the function of the ventral tegmental area (VTA) circuits in the learning and performance of motivated behaviors. The research aims to use bidirectional optogenetics, in vivo electrophysiology and photometry, and quantitative behavioral measures to investigate the contributions of VTA dopamine and GABA neurons...
This federal Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), is providing $121,364 to the University of California, Los Angeles (UCLA) to conduct critical investigation into the neural circuitry that supports goal-directed and habit learning. The research will use advanced techniques such as optogenetic manipulation and in vivo fiber photometry to study the role of dopaminergic projections from the ventral...
This federal Project Grant award in the amount of $149,284 from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) will support research at Vanderbilt University to define how chronic cocaine use disrupts the dopaminergic control of striatal activity. The research aims to 1) establish the precise temporal conditions under which dopamine modulates the activity of genetically-defined medium spiny neuron populations in the nucleus...
This $189,644 Project Grant award from the National Institute on Drug Abuse (NIDA), funded under the Drug Use and Addiction Research Programs (CFDA 93.279), supports research to characterize and functionally validate several transcript variants of the dopamine D3 receptor (DRD3) gene in the context of cocaine addiction. The project aims to: 1) Characterize the functions of DRD3 transcript variants using heterologous expression systems; and 2) Develop and validate neuron type-specific...
This federal Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $587,162 to Virginia Commonwealth University (VCU) to investigate the role of norepinephrine transporter (NET) phosphorylation in amphetamine reward and substance use disorder. The research project aims to use cutting-edge techniques, including a NET phosphorylation-defective mouse model and viral-mediated brain region-specific...
This Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), will provide $284,040 to The Lieber Institute for Brain Development to conduct research on the molecular and circuit-level changes in the habenula brain region associated with opioid exposure. The study aims to generate a spatially-resolved atlas of opioid-induced gene expression changes in the rodent habenula at the cellular and circuit level, and to...

MOLECULAR AND FUNCTIONAL CHARACTERIZATION OF TRANSCRIPTIONALLY DEFINED SUBPOPULATIONS OF VTA DOPAMINE NEURONS - PROJECT SUMMARY SUBSTANCE USE DISORDER IS A COMPLEX NEUROBIOLOGICAL DISEASE CHARACTERIZED BY A LOSS OF CONTROL OVER DRUG-TAKING AND DRUG-SEEKING BEHAVIORS. FURTHER EXACERBATED BY THE COVID-19 PANDEMIC, THE RATE OF DRUG-RELATED OVERDOSES AND SUBSEQUENT DEATHS HAS INCREASED DRAMATICALLY OVER THE PAST DECADE, SURPASSING 107,000 IN 2022. ALL DRUGS OF ABUSE INCREASE DOPAMINE (DA) TRANSMISSION WITHIN THE NUCLEUS ACCUMBENS (NAC) FROM DA PROJECTIONS FROM THE VENTRAL TEGMENTAL AREA (VTA). WHILE THE PRESENCE OF TYROSINE HYDROXYLASE (TH) HAS LONG BEEN USED TO IDENTIFY DA NEURONS, MORE RECENT STUDIES HAVE REVEALED REMARKABLE HETEROGENEITY AMONG VTA DA NEURONS, WITH SOME NEURONS CO-EXPRESSING MARKERS FOR BOTH DA AND GLUTAMATE (GLUT) TRANSMISSION THAT ARE SIMILARLY TH+. HOWEVER, THE ROLE OF DA-ONLY COMPARED TO COMBINATORIAL CELLS IN SUBSTANCE USE DISORDER IS CURRENTLY UNKNOWN. USING SINGLE NUCLEUS RNA SEQUENCING TO COMPREHENSIVELY PROFILE THE VTA, WE PREVIOUSLY IDENTIFIED UNIQUE MARKERS FOR THESE TWO SUBPOPULATIONS OF DA NEURONS. SLC26A7, A GENE THAT ENCODES AN ANION TRANSPORTER, SERVES AS A SELECTIVE MARKER FOR COMBINATORIAL NEURONS THAT HARBOR EXPRESSION OF GENES IMPLICATED IN BOTH GLUT AND DA SYNTHESIS AND NEUROTRANSMISSION. LIKEWISE, THE GTP CYCLOHYDROLASE GCH1 WAS IDENTIFIED AS A MARKER FOR DA-ONLY NEURONS. USING A FLUORESCENT IN SITU HYBRIDIZATION PROTOCOL, I VALIDATED THESE FINDINGS SHOWING THE SLC26A7 MARKS DA+/GLUT+ CELLS WHILE GCH1 MARKS DA+/GLUT- CELLS. I HAVE SHOWN UNIQUE INDUCTION OF THE NEURONAL ACTIVITY MARKER FOS IN SLC26A7+ CELLS IN THE VTA 1 HOUR FOLLOWING COCAINE, BUT NOT FENTANYL, EXPERIENCE; THIS SAME RESPONSE WAS NOT OBSERVED IN GCH1+ CELLS, SUGGESTING A DIFFERENCE IN RESPONSE TO COCAINE BETWEEN THESE TWO DISTINCT DA NEURON POPULATIONS. THESE RESULTS SUGGEST THAT TWO SUBPOPULATIONS OF DAERGIC CELLS IN THE VTA RESPOND TO COCAINE IN UNIQUE WAYS AND MAY IN TURN DRIVE DISTINCT DOWNSTREAM EFFECTS AND BEHAVIORAL RESPONSES TO COCAINE. FOLLOWING THESE FINDINGS, I HYPOTHESIZE THAT DIFFERENCES IN CELLULAR TARGETS AND NEUROPHYSIOLOGY CONFER DISTINCT BEHAVIORAL ROLES OF DA SUBPOPULATIONS. USING THESE SELECTIVE MARKERS, I HAVE DESIGNED AND GENERATED NOVEL ADENO-ASSOCIATED VIRUSES (AAVS) TO BOTH EXPRESS DISTINCT FLUOROPHORES AND MANIPULATE THE NEURONS IN A CELL-TYPE SPECIFIC WAY. USING THESE AAVS, THIS PROJECT AIMS TO TAKE A MULTIDISCIPLINARY APPROACH TO RIGOUROUSLY INVESTIGATE AND DETERMINE ANY DIFFERENCES IN CELL TYPES THROUGH THE FOLLOWING AIMS: (1) CHARACTERIZE ANATOMICAL AND CELLULAR LOCALIZATION OF PROJECTIONS, (2) DETERMINE NEUROPHYSIOLOGICAL DIFFERENCES, AND (3) DETERMINE THE ROLE OF COMBINATORIAL CELLS IN BEHAVIOR. THE PROPOSED STUDIES WILL DEEPEN OUR UNDERSTANDING OF THE ROLE OF THESE COMBINATORIAL CELLS IN SUD, PROVIDING AVENUES FOR THERAPEUTIC EXPLORATION FOR A DISEASE LARGELY LACKING TREATMENT OPTIONS. UNDER THIS AWARD, I WILL MASTER BEHAVIORAL PARADIGMS AND ELECTROPHYSIOLOGY, TECHNIQUES THAT WILL AID MY SUCCESS AS A PHYSICIAN-SCIENTIST.

Posted 12/19/24, 12:00 AM